Overview
Lukas Bariswyl practices practicing medicine in Bern, Switzerland.
His clinical expertise encompasses Pancreatic Ductal Adenocarcinoma, Melanoma, and Lung Metastases.
He is actively involved in clinical research, co-authoring 11 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Lukas Bariswyl
Is Lukas Bariswyl a top-rated expert for Pancreatic Ductal Adenocarcinoma?
MediFind is an objective health platform that identifies experts based on real-world data. Lukas Bariswyl is classified as an Experienced expert for Pancreatic Ductal Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Lukas Bariswyl participate in research or clinical trials?
Yes. Lukas Bariswyl has published 11 articles and abstracts on conditions like Pancreatic Ductal Adenocarcinoma. You can view a list of Lukas Bariswyl's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Lung MetastasesMr. Bariswyl isExperienced. Learn about Lung Metastases.
- MelanomaMr. Bariswyl isExperienced. Learn about Melanoma.
- Pancreatic Ductal AdenocarcinomaMr. Bariswyl isExperienced. Learn about Pancreatic Ductal Adenocarcinoma.